Supplementary Data



SUPPLEMENTARY FIG. S1. Noggin treatment suppresses the enhanced osteogenic differentiation elicited by SB431542. **(A)** Mineralization of the extracellular matrix detected by alizarin red staining performed on untreated, SB431542, and SB431542 plus noggin (250 ng/mL)-treated POb cells clearly demonstrates that noggin suppresses the robust osteogenic differentiation observed in SB431542-treated POb cells. **(B)** Quantification of alizarin staining showing a significant decrease in mineralization in POb cells undergoing osteogenic differentiation with 10 μM SB431542 plus 250 ng/mL noggin. **(C)** Expression of *Bglap* is dramatically downregulated in the presence of noggin in POb cells treated with SB431542 as indicated by PCR analysis. **(D)** Alizarin red staining performed on untreated, SB431542, and SB431542 plus noggin (250 ng/mL)-treated DM cells indicates that noggin treatment abrogates also in these cells the enhanced osteogenesis triggered by SB431542. **(E)** Quantification of alizarin red staining shown in **(D)**. **(F)** PCR analysis performed on DM cells shows similar downregulation of late osteogenic marker *Bglap* when cells are cotreated with SB431542 and noggin. DM, dura mater; POb, parietal bone osteoblast.